Northeast Ohio Medical University, CEL-SCI produce new investigational breast cancer vaccine

In partnership with CEL-SCI Corporation, Northeast Ohio Medical University (NEOMED) has produced a new investigational breast cancer vaccine. In animal tests the J-HER vaccine has shown reduction of HER-2/neu expressing breast cancer tumors, reduction mass, absence of tumor in lymph nodes or peritoneal membranes, and changes in angiogenesis.

Dr. Rosenthal, Sarah Stone and Robin Edmonds from NEOMED worked with CEL-SCI’s Dr. Daniel Zimmerman to design and test the LEAPS (Ligand Epitope Antigen Presentation System) technology vaccine. 

Present in most human breast tumor cells, the HER-2/neu protein is the target for different types of immunotherapy with sales of many billions of dollars.  Blocking this receptor protein with an antibody causes the tumor cells to commit suicide, or apoptosis. The J-HER vaccine activates a T lymphocyte response targeted to this protein that promotes killing and control of the tumor cell. In these studies, mice were immunized with the vaccine before, or one week after implantation of HER-2/neu breast cancer cells. In both cases the immune response initiated by the immunization significantly blocked further development and progression of tumors in most of the animals.

More details on the vaccine and technology available here.

NEOMED is located in Rootstown, Ohio. CEL-SCI has operations in Vienna, Virginia, and Baltimore, Maryland.

Recent Posts

Blog Post Archive

Blog Post Categories

Search the Blog

Newsticker


BioOhio Member Mark BioOhio Member

University of Toledo Medical Center’s new $36M simulator makes training nearly real | Toledo Blade, April 23, 2014

Aerpio Therapeutics closes $22M financing led by OrbiMed (pdf) | Aerpio Therapeutics, April 23, 2014

CTI Clinical Trial & Consulting Services continues to grow with promotions and new hires | Cincinnati.com, April 22, 2014

Austen BioInnovation Institute in Akron presenting two FDA events in one day, April 29 | Austen BioInnovation Institute in Akron, April 22, 2014

OSU collaboration with California’s Oakbio awarded $500k from Canada’s CCEMC to develop biofuels | PR Newswire, April 22, 2014

OSU students’ non-polluting KAir battery wins $100K from US DOE | Columbus Business First, April 22, 2014

The Medical Imaging Technology Partnering Forum part of Cleveland’s medical imaging strength | Cleveland.com, April 22, 2014

Akebia Therapeutics stock rose 55% last week, from below $17 to above $26 | Cincinnati Business Courier, April 21, 2014

The Austen BioInnovation Institute in Akron working with Nottingham Spirk, a Cleveland-based design firm | Akron Beacon Journal, April 21, 2014

CincyTech discusses recent funding for Assurex Health & Sirrus (Bioformix) | Cincinnati Business Courier, April 21, 2014

Akron Children’s joins with Cincinnati Children’s to offer access to new cancer treatments | Akron Beacon Journal, April 20, 2014

OSU Biomedical Engineering students and OncoFilter partners Kinshuk Mitra and Brett Geiger featured on 10TV Columbus | WBNS 10TV Columbus, April 19, 2014

Case Western Reserve University event emphasizes a constellation of research (slideshow) | Cleveland.com, April 19, 2014

Airway Therapeutics granted orphan designation for its product to prevent BPD by European regulatory authority | Cincinnati.com, April 19, 2014

Assurex Health and Sirrus (Bioformix) lead 2014 Q1 funding rounds | Cincinnati.com, April 18, 2014

PhRMA Annual Meeting keynote speakers available on YouTube | PhRMA, April 18, 2014

Alkermes CEO Richard Pops speaks with Xconomy about building the business | Xconomy.com, April 18, 2014

Case Western Reserve University scientists discuss a portable malaria detector (video) | Inside Science TV, April 18, 2014

Ashland University Schar Nursing College starts Doctor of Nursing Program | WMFD Mansfield, April 18, 2014

Kent State Researchers discover new liquid crystal structure | Kent State University, April 17, 2014